Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-11-27 | aflibercept | Bayer Healthcare (Germany) Regeneron Pharmaceuticals (USA - NY) | neovascular form of age-related macular degeneration (wet AMD) |
Granting of a Market Authorisation in the EU |
2012-02-20 | vemurafenib | Roche (Switzerland) | BRAF V600 mutation-positive metastatic melanoma | Granting of a Market Authorisation in the EU |
2011-12-20 | concentrate of catechins with a complex defined composition, extracted from green tea leaves | Medigene (Germany) | genital warts |
Submission of a Market Application in the EU |
2011-12-20 | telavancin | Astellas (Japan) Theravance (USA) | nosocomial pneumonia, known or suspected to be caused by methicillin¬resistant Staphylococcus aureus (MRSA) | |
2017-06-22 | liraglutide | Novo Nordisk (Denmark) |
|
Granting of a Market Authorisation in the US |
2011-07-18 | boceprevir | Merck&Co (USA) | chronic hepatitis-C genotype-1 infection |
Granting of a Market Authorisation in the EU |
2013-09-19 | everolimus | Novartis (Switzerland) | treatment of patients 3 years of age and older, with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), for whom surgery is not a suitable option | Granting of a Market Authorisation in the EU |
2011-12-20 | rivaroxaban | Bayer Healthcare (Germany) | stroke prevention in patients with atrial fibrillation (SPAF) | Granting of a Market Authorisation in the US |
2011-12-20 | paliperidone palmitate | Janssen-Cilag International -J&J (USA) | maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone |
Granting of a patent |
2011-12-20 | denosumab | Amgen (USA) | prevention of skeletal-related events in adults with bone metastases from solid tumour | Granting of a Market Authorisation in the EU |
2011-12-20 | bromfenac | Croma-Pharma (Austria) | postoperative ocular inflammation following cataract extraction in adults | |
2017-12-14 | ipilimumab | BMS (USA - NY)) |
|
Positive opinion for the granting of a Market Authorisation in the EU |
2011-12-20 | nomegestrol acetate/estradiol | Merck Serono (Germany) Teva Pharmaceuticals (Germany) | oral contraception | Granting of a Market Authorisation in the EU |
2011-12-20 | Nanobodies targeting TNF-alpha including ATN-103 (ozoralizumab) and PF-05230905 | Ablynx (Belgium) | rheumatoid arthritis |
Granting of a patent |
2014-10-21 | resminostat | 4SC (Germany) | Hodgkin's Lymphoma |
Granting of a patent |
2012-01-01 | rigerimod | ImmuPharma (UK) | systemic lupus erythematosus |
Granting of a patent |
2011-12-20 | (drotrecogin alfa (activated)) | Eli Lilly (USA) | severe sepsis in adult patients with multiple organ failure, in addition to best standard care | |
2011-12-20 | sitagliptin and pioglitazone | Merck&Co (USA) | type II diabetes mellitus |
Withdrawal of the product |
2011-12-20 | ecallantide | Dyax (USA - MA) | hereditary angioedema |
Granting of a Market Authorisation in the US |
2012-04-21 | ruxolitinib | Incyte (USA - DE) ) Novartis (Switzerland) | myelofibrosis |
Granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+